Ruetten Hannah M, Lankford Shannon S, Abdolmaleki Abolfazl S, Edenhoffer Nicholas, Badlani Gopal, Williams James K
Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States.
Department of Pathology, Section on Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States.
Am J Physiol Gastrointest Liver Physiol. 2025 Feb 1;328(2):G136-G144. doi: 10.1152/ajpgi.00343.2024. Epub 2025 Jan 2.
This study aimed to determine if local injection of C-X-C motif chemokine ligand 12 (CXCL12) reduces sphincter fibrosis, restores sphincter muscle content, vascularization, and innervation, and recruits progenitor cells in a rabbit model of anal sphincter injury and incontinence. Adult female rabbits were assigned to three groups: uninjured/no treatment (control), injured/treated (treated), and injured/no treatment (untreated) ( = 4 each). Injured groups were anesthetized, and a section of external anal sphincter was removed at the 9 o'clock position. The treated sphincters were injected with 200 ng of human recombinant CXCL12 6 wk after injury, and necropsy was performed 6-wk post-treatment. The external anal sphincter was removed, fixed, embedded in paraffin, sectioned, and mounted to slides for histologic analysis of collagen and muscle content and fiber characteristics: innervation, vascularization, and progenitor cell content. Compared with controls, untreated had significantly decreased total skeletal muscle, indistinct muscle layers, and disorganized circumferential and inner longitudinal layers at the injury site. Untreated also had significantly increased collagen fiber density at the injury site compared with treated and controls. Cells staining positive for CD34 within the skeletal muscle layer were increased in treated and untreated compared with controls. Staining density for markers of nerves and vascular endothelium, cells staining positive for CD34 within the mucosa/submucosae, and cells staining positive for PAX7 were similar among all groups. Local injection of CXCL12 reduces postinjury fibrosis and results in statistically similar muscle content and organization between treated animals and controls. Further studies are needed for this promising new treatment for postparturient anal sphincter injury. Local injection of CXCL12 cytokine reduces postinjury fibrosis in a rabbit model of anal sphincter injury and fecal incontinence. The larger size of the rabbits aided in targeted injury and treatment. Further studies are needed to explore noninvasive treatment options for postparturient anal sphincter injury.
本研究旨在确定在兔肛门括约肌损伤和失禁模型中,局部注射C-X-C基序趋化因子配体12(CXCL12)是否能减少括约肌纤维化、恢复括约肌肌肉含量、血管化和神经支配,并募集祖细胞。成年雌性兔被分为三组:未受伤/未治疗(对照组)、受伤/治疗(治疗组)和受伤/未治疗(未治疗组)(每组n = 4)。对受伤组进行麻醉,并在9点位置切除一段肛门外括约肌。治疗组在损伤后6周注射200 ng人重组CXCL12,治疗后6周进行尸检。切除肛门外括约肌,固定,石蜡包埋,切片,贴于载玻片上,用于胶原和肌肉含量以及纤维特征的组织学分析:神经支配、血管化和祖细胞含量。与对照组相比,未治疗组损伤部位的总骨骼肌明显减少,肌层不清晰,环行和内环行层排列紊乱。与治疗组和对照组相比,未治疗组损伤部位的胶原纤维密度也显著增加。与对照组相比,治疗组和未治疗组骨骼肌层中CD34染色阳性的细胞增加。所有组中神经和血管内皮标志物的染色密度、黏膜/黏膜下层中CD34染色阳性的细胞以及PAX7染色阳性的细胞相似。局部注射CXCL12可减少损伤后纤维化,使治疗动物与对照组之间的肌肉含量和组织结构在统计学上相似。对于这种有前景的产后肛门括约肌损伤新治疗方法,还需要进一步研究。局部注射CXCL12细胞因子可减少兔肛门括约肌损伤和大便失禁模型中的损伤后纤维化。兔体型较大有助于进行靶向损伤和治疗。需要进一步研究探索产后肛门括约肌损伤的非侵入性治疗选择。